It doesn't matter whether a biosimilar sponsor dances the steps choreographed in the Biologics Price Competition and Innovation Act (BPCIA), the Federal Circuit ruled Tuesday. It still cannot serve the reference biologic maker with the required 180-day notice of commercial marketing until after the FDA licenses the biosimilar.